Difference between revisions of "Rezvilutamide (SHR-3680)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
m |
||
| Line 12: | Line 12: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | [[Category: | + | [[Category:Second-generation nonsteroidal antiandrogens]] |
[[Category:Prostate cancer medications (investigational)]] | [[Category:Prostate cancer medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Revision as of 11:04, 4 July 2023
Mechanism of action
A nonsteroidal antiandrogen.
Preliminary data
Prostate cancer
- CHART: Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. link to original article PubMed Clinical Trials Registry
Also known as
- Code name: SHR3680